Background: To determine the incidence of SRs to P and ID tests, the response to stat epi IM, number of delayed SRs, the dose of epi IM versus BMI and the World Allergy Organization (WAO) Grade (1-5) of the SRs. Methods: SRs were compiled from 07/2010 to 06/2011 to P and ID tests for any combination of approximately 20 allergens (pollens, animal emanations, molds and Hymenoptera) in 1,332 subjects. Nurses administered stat epi IM (1:1000 v/v), 0.2 mg IM, into the arm or thigh for any signs or symptoms (SS) of a SR, including, but not limited to, itchy eyes, nose, pharynx, or palms; rhinorrhea, nasal congestion, sneezing; and generalized erythema, skin pruritus, or urticaria. SS (WAO Grade), total epi IM dose, and delayed SRs were recorded. Repeat doses of epi IM were given if SS persisted or worsened. Results: 31 (2%) had SRs: 24 (77%) female, 7 (23%) male; 5 (16%) pediatric, 26 (84%) adult. Of the 31 SRs, 26 (84%) had Grade 1, 5 (16%) Grade 2 and Grades 3 to 5. 13 (42%) experienced SS during P and 18 (58%) during ID or at the completion of P and ID. All received stat epi IM with any SS. 2 BMIs were not available. 28 SRs, with a mean BMI of 28.5 (overweight range 25.0-29.9) received one epi IM, 0.2 mg, and one BMI 20.4 (normal range 18.5-24.9) received 2 epi IM (total 0.3 mg). There were no underweight (less than 18.5) or obese (30.0 or greater) subjects. Background: Despite the increase of allergic diseases over the last decades, the population ignores the basic concepts, interfering in their prevention and treatment. The "Allergy Blog" (Blog da Alergia) has been using digital media resources to offer new forms of dialogue and patient s ethical enlightenment since 1996. This research objective to report the interactive educational experience, through the internet on "http://www.blogdalergia.com" and to find out, from the audience's questions, which are the main areas of interest about immune-allergic diseases. Methods: Research on 1375 e-mails randomly selected, sent to the Blog home page, to know what were the main issues raised by the lay public. The e-mails were analyzed, considering the gender and age of the users and the topic searched. Results: Since 1996, Allergy Blog answered 4,256 e-mails and 2,200 comments. Most of patients were female: 78.2%, compared with 19.9% male and 1.9% with no information. Many users (67.65%) did not reported their age, as there wasn't a mandatory item for this question. But, 25.38% of the users were parents or guardians of children with allergic disease. The frequency of the most popular topics searched were: Urticaria (14,55%), Doubts about drugs (12.51%), Allergic Rhinitis (10,98%), Pruritus (8,15%), Asthma (8, 87%), Contact dermatitis (5,60%), Atopic Dermatitis (4,58%), Drug Allergy (2,47%), Cough (3,86%), and Others (6,40%). Dermatologic manifestations of allergy bring more questions than the respiratory ones (32.9% versus 23.7%), and drug concerns responded for 14.9% of the doubts. Asthma, for which there are a lot of educative campaigns, represented only 8.9% of the questions. To clarify these questions, Allergy Blog published educational texts and interacted with the visitors through: a) Comments on Blog posted questions, 2) Answers to doubts sent via e-mail, 3) Chat intended for short answers.
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Conclusions:
The discoveConclusions: The discovery of the lay's greatest gaps and areas of interest can be a guideline to improve new educative actions in Allergy and Immunology. The use of digital media and social networks may be a prime tool for the education of allergic individuals, community dialogue and dissemination of correct information about the various aspects of immune-allergic diseases.
Anaphylaxis after Anesthetic Reversal
Sendy Chugo, MD. Allergy, MIR, Navarra, Spain. Background: Sugammadex is a new drug used for the reversal of neuromuscular blockade by rocuronium or vecuronium, a muscle relaxant used as fast acting. Methods: We performed a review of a case of a patient scheduled for osteosynthesis of the ankle with a history of bronchial asthma and sensitization to Dermatophagoides pteronyssinus. After the surgery the patient suffered anaphylaxis, a minute after the use of sugammadex. Results: We evaluated the drugs used during anesthesia Prick and intradermal, and we obtained positive results with Sugammadex at 1 month, 3 and 6 months. We performed the basophil activation test giving a positive result. Tests show IgE-mediated sensitization with positive skin tests and basophil activation test. Conclusions: It is believed that prior sensitization may have occurred due to ingestion of cyclodextrins which is present in many foods. The atopic status of this patient may have had some awareness of cyclodextrins. This case has been published as the first documented case of anaphylaxis by sugammadex with normal doses. Our case raises clear that the underlying mechanism of this reaction was an IgE-mediated sensitization. Background: Upper airway inflammation could be reflected by nasal lavage cytology test, which is characterized by advantages of non-invasive, simple, objective and costless. However, reference values nasal lavage cytology was not established. To establish reference values and positive standard for nasal lavage cytology through screening normal healthy subjects and patients with allergic rhinitis according to strict inclusion criteria. Methods: To establish reference values and positive standard for nasal lavage cytology through screening normal healthy subjects and patients with allergic rhinitis according to strict inclusion criteria. Results: There was no statistical significance in gender constitutional proportion, age, height and weight among each group. 95% CI of neutrophils, eosinophils was (0w12.61)/·200 and (0w1.70)/·200, respectively. The median (interquartile range) of neutrophils were 0(0.65)/·200 in AR group, which showed no statistical difference (P . 0.05) with that of normal group [0(0)/·200]. A significant difference was found in the median (interquartile range) of eosinophils [6.90(22.40) /·200] in AR group as compared with that of normal control group [0(0.10)/·200, P , 0.001]. Conclusions: Establishment of reference values of nasal lavage cytology test is helpful to discriminate normal individuals and patients with allergic rhinitis, but also a non-invasive tool for objective reflection on upper airway inflammation, which is of great value for scientific and clinical purposes. Background: We present a post hoc analysis from 3 phase III clinical trials examining the effects of mometasone furoate/formoterol (MF/F) combination therapy on asthma deterioration in subjects previously not well controlled on low-, medium-, or high-dose inhaled corticosteroids (ICS). Methods: A 2-to 3-week run-in period with twice-daily (BID) MF 100 mg (MF/F 100/10 mg BID study), MF 200 mg (MF/F 200/10 mg BID study), or MF 400 mg (MF/F 400/10 mg BID study) was performed before subjects (aged $12 years) were randomized to BID: MF/F 100/10 mg, MF 100 mg, F 10 mg, or placebo for 26 weeks (n ¼ 746; MF/F 100/10 mg BID study); MF/F 200/10 mg, MF 200 mg, F 10 mg, or placebo for 26 weeks (n ¼ 781; MF/F 200/10 mg BID study); or MF/F 200/10 mg, MF/F 400/10 mg, or MF 400 mg for 12 weeks (n ¼ 728; MF/F 400/10 mg BID study). Assessment of asthma deterioration (ie, 20% decrease in forced expiratory volume in 1 s [FEV 1 ], 30% decrease in peak expiratory flow [PEF] on $2 consecutive days, or clinically judged deterioration [ie, emergency treatment, hospitalization, or treatment with excluded medications]) was a coprimary endpoint for the MF/ F 100/10 mg BID and 200/10 mg BID studies and a secondary endpoint for the MF/F 400/10 mg BID study. Post hoc pair-wise comparisons of pooled MF/F vs pooled MF, F, and placebo treatment groups were performed. Results: Sample sizes in this pooled analysis were 861 for MF/F, 620 for MF, 390 for F, and 384 for placebo. There was a significantly lower incidence of asthma deterioration with MF/F (17.2%) versus MF (26.1%; P ¼ 0.002), F (49.5%; P , 0.001), and placebo (50.8%; P , 0.001). Incidence of individual asthma deterioration criteria was 7.0% for MF/F, 10.0% for MF, 13.8% for F, and 17.7% for placebo for FEV 1 reduction; 7.5%, 12.6%, 27.2%, and 26.3%, respectively, for PEF reduction; and 2.1%, 2.6%, 6.7%, and 5.2% for clinically judged deterioration. Conclusions: MF/F-treated subjects experienced a significantly lower rate of asthma deterioration compared with MF, F, and placebo in subjects previously not well controlled on low-, medium-, or high-dose ICS. Background: Mometasone furoate/formoterol (MF/F) combination therapy is a new treatment recently approved by the US Food and Drug Administration for the treatment of persistent asthma and currently under regulatory review by Canadian authorities. We report findings from a noninferiority study that compared effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma. Methods: This randomized, active-controlled, multicenter, noninferiority trial enrolled subjects (aged $12 years) previously treated with medium-dose inhaled corticosteroid alone or combined with a long-acting b 2 -agonist. Following a 2-to 4-week run-in treatment period with MF administered via a metered-dose inhaler (MDI) 200 mg twice daily (BID), eligible subjects were randomized to MF/F-MDI 200/10 mg BID or FP/S administered via a dry powder inhaler (DPI) 250/50 mg BID for 12 weeks. The primary endpoint of this trial was change from baseline in area under the curve (AUC) in forced expiratory volume in 1 second (FEV 1 ) measured serially for 0 to 12 hours postdose (FEV 1 AUC 0212h ). Key secondary endpoints included onset of action, defined as change from baseline in FEV 1 at 5 minutes postdose on day 1. Results: 722 subjects were randomized to MF/F-MDI (n ¼ 371) or FP/S-DPI (n ¼ 351). The trial's primary endpoint was met, demonstrating that MF/F administered via an MDI was noninferior to FP/S administered via a DPI in the patient population investigated. Mean FEV 1 AUC 0212h at endpoint for MF/F-MDI and FP/S-DPI was 3.43 versus 3.24 L · h, respectively (95%, CI, 20.40 to 0.76). Analysis of onset-of-action characteristics revealed that MF/ F's effect on lung function occurred significantly faster than the effect observed with FP/S-DPI. MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV 1 at 5 minutes postdose (first scheduled measurement) on the first day of treatment vs a 90-mL increase for FP/S-DPI (P , 0.001).
ASTHMA TREATMENT
Conclusions: This trial demonstrated that MF/F 200/10 mg BID administered via an MDI was noninferior to FP/S 250/50 mg BID administered via a DPI in its effect to improve lung function as measured by FEV1 AUC0-12h. However, the onset of action for this effect was significantly faster with MF/F-MDI than with FP/S-DPI. 
